SMT202000423T1 - Terapie di aumento genico per degenerazione retinica ereditaria causata da mutazioni del gene prpf31 - Google Patents

Terapie di aumento genico per degenerazione retinica ereditaria causata da mutazioni del gene prpf31

Info

Publication number
SMT202000423T1
SMT202000423T1 SM20200423T SMT202000423T SMT202000423T1 SM T202000423 T1 SMT202000423 T1 SM T202000423T1 SM 20200423 T SM20200423 T SM 20200423T SM T202000423 T SMT202000423 T SM T202000423T SM T202000423 T1 SMT202000423 T1 SM T202000423T1
Authority
SM
San Marino
Prior art keywords
gene
mutations
prpf31
retinal degeneration
degeneration caused
Prior art date
Application number
SM20200423T
Other languages
English (en)
Inventor
Eric A Pierce
Michael H Farkas
Maria E Sousa
Original Assignee
Massachusetts Eye & Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary filed Critical Massachusetts Eye & Ear Infirmary
Publication of SMT202000423T1 publication Critical patent/SMT202000423T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SM20200423T 2015-03-06 2016-03-07 Terapie di aumento genico per degenerazione retinica ereditaria causata da mutazioni del gene prpf31 SMT202000423T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562129638P 2015-03-06 2015-03-06
US201562147307P 2015-04-14 2015-04-14
PCT/US2016/021226 WO2016144892A1 (en) 2015-03-06 2016-03-07 Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene
EP16762307.3A EP3265568B1 (en) 2015-03-06 2016-03-07 Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene

Publications (1)

Publication Number Publication Date
SMT202000423T1 true SMT202000423T1 (it) 2020-09-10

Family

ID=56879585

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200423T SMT202000423T1 (it) 2015-03-06 2016-03-07 Terapie di aumento genico per degenerazione retinica ereditaria causata da mutazioni del gene prpf31

Country Status (15)

Country Link
US (3) US20180043034A1 (it)
EP (2) EP3748007B1 (it)
JP (3) JP6812368B2 (it)
CY (1) CY1123158T1 (it)
DK (1) DK3265568T3 (it)
ES (1) ES2806054T3 (it)
HR (1) HRP20201225T1 (it)
HU (1) HUE051491T2 (it)
LT (1) LT3265568T (it)
PL (1) PL3265568T3 (it)
PT (1) PT3265568T (it)
RS (1) RS60668B1 (it)
SI (1) SI3265568T1 (it)
SM (1) SMT202000423T1 (it)
WO (1) WO2016144892A1 (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
EP3003391B1 (en) 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
EP3748007B1 (en) * 2015-03-06 2024-06-26 Massachusetts Eye & Ear Infirmary Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
AU2017302013B2 (en) 2016-07-29 2022-05-26 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
CA3061968A1 (en) 2017-05-10 2018-11-15 Massachusetts Eye And Ear Infirmary Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
CA3053154A1 (en) 2017-06-30 2019-01-03 The Regents Of The University Of California Adeno-associated virus virions with variant capsids and methods of use thereof
JP2020534788A (ja) 2017-08-28 2020-12-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アデノ随伴ウイルスカプシド変異体及びその使用方法
CN112204145B (zh) * 2018-06-01 2024-03-26 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的组合物和方法
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US20220152278A1 (en) * 2019-03-15 2022-05-19 University Of Washington Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
EP4117644A4 (en) * 2020-03-11 2024-08-14 Massachusetts Eye and Ear Infirmary GENE THERAPY FOR NMNAT1-ASSOCIATED RETINAL DEGENERATION
JP7778400B2 (ja) * 2021-06-16 2025-12-02 北京中因科技有限公司 Prpf31変異体およびその使用
JP2025534556A (ja) * 2022-10-21 2025-10-16 バイオジェン・エムエイ・インコーポレイテッド 網膜色素変性症を治療するための組成物及び方法
WO2024123461A1 (en) * 2022-12-05 2024-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pigment epithelium-derived factor peptides and use for treating retinal degeneration

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
US6569662B1 (en) * 2000-01-21 2003-05-27 Hyseq, Inc. Nucleic acids and polypeptides
WO2002082904A2 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
US20040208847A1 (en) * 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
US8211634B2 (en) * 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2140004B1 (en) * 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
WO2009134681A2 (en) * 2008-04-30 2009-11-05 The Trustees Of The University Of Pennsylvania Aav7 viral vectors for targeted delivery of rpe cells
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
WO2015189429A1 (en) * 2014-06-13 2015-12-17 Universidade De Santiago De Compostela Nanoparticulate systems for use in gene transfer or gene delivery
EP3748007B1 (en) 2015-03-06 2024-06-26 Massachusetts Eye & Ear Infirmary Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene

Also Published As

Publication number Publication date
SI3265568T1 (sl) 2020-10-30
EP3265568A1 (en) 2018-01-10
LT3265568T (lt) 2020-08-25
JP2021059561A (ja) 2021-04-15
JP2023071867A (ja) 2023-05-23
HUE051491T2 (hu) 2021-03-01
EP3748007A1 (en) 2020-12-09
RS60668B1 (sr) 2020-09-30
JP2018511652A (ja) 2018-04-26
WO2016144892A1 (en) 2016-09-15
HK1247637A1 (en) 2018-09-28
HRP20201225T1 (hr) 2020-11-13
EP3265568B1 (en) 2020-05-06
ES2806054T3 (es) 2021-02-16
DK3265568T3 (da) 2020-08-10
PT3265568T (pt) 2020-08-20
EP3748007B1 (en) 2024-06-26
JP7239550B2 (ja) 2023-03-14
JP6812368B2 (ja) 2021-01-13
CY1123158T1 (el) 2021-10-29
US20210069347A1 (en) 2021-03-11
EP3265568A4 (en) 2018-08-08
US20250195691A1 (en) 2025-06-19
PL3265568T3 (pl) 2020-11-30
EP3748007C0 (en) 2024-06-26
US20180043034A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
SMT202000423T1 (it) Terapie di aumento genico per degenerazione retinica ereditaria causata da mutazioni del gene prpf31
IL251468A0 (en) aav-based gene therapy
GB201512869D0 (en) Gene signature for minute therapies
IL252442A0 (en) Combined treatments
ZA201802462B (en) Gene therapy
PL3356313T3 (pl) 2-perfluoroheksylooktan do podawania okulistycznego
GB201420139D0 (en) Factor IX gene therapy
GB201507781D0 (en) Blending techniques for curve fitting
ZA201704793B (en) Treatment of retinal degeneration using progenitor cells
GB201407322D0 (en) Gene therapy
GB201401886D0 (en) Neurodegenerative therapies
PT3253208T (pt) Terapêuticas de combinação para utilização no tratamento do cancro da mama
AU201611738S (en) Lawnmower seat
SG11201707117SA (en) Ophthalmic composition
SG10201506616PA (en) Anodes for use in biocompatible energization elements
AU201611722S (en) Lawnmower seat
PL3050465T3 (pl) Mebel do siedzenia
EP3708680B8 (en) Compositions and methods for xi chromosome reactivation
AU201611740S (en) Lawnmower seat
GB201523035D0 (en) In terferometry
GB201513151D0 (en) Functional gene replacement therapy
GB201503246D0 (en) Online health audit
AU2014900238A0 (en) Improvements in online trading
HK1244501A1 (en) Aav-based gene therapy
PL3165235T3 (pl) Białka do stosowania do zwalczania ptaszyńców kurzych